Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 in Noninfectious Uveitis
NCT00685399Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2008
- Primary completion
- Sep 2013
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of secukinumab in noninfectious uveitis (NIU) (8 cohorts), sponsored by Novartis. Primary endpoint: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Who Died. Started Jun 2008; status: completed.
02
Drugs
secukinumab
03
Conditions
noninfectious uveitis (NIU)
Beyond the preview
Go deeper on NCT00685399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00685399.